2. Search Result
Search Result
Isoforms Recommended: HSP90
Results for "

Hsp90β

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Peptides

1

Natural
Products

1

Recombinant Proteins

8

Antibodies

3

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15785
    Pimitespib
    5+ Cited Publications

    TAS-116

    		 HSP Cancer
    Pimitespib (TAS-116) is an oral bioavailable, ATP-competitive, highly specific HSP90α/HSP90β inhibitor (Kis of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94 . Pimitespib demonstrates less ocular toxicity .
    Pimitespib
  • HY-10215
    Luminespib
    Maximum Cited Publications
    25 Publications Verification

    VER-52296; AUY922; NVP-AUY922

    		 HSP Autophagy Apoptosis Cancer
    Luminespib (VER-52296) is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .
    Luminespib
  • HY-15190
    NVP-HSP990
    4 Publications Verification

    Hsp-990

    		 HSP Apoptosis Cancer
    NVP-HSP990 is a potent, selective and orally active Hsp90 inhibitor, with IC50 values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.
    NVP-HSP990
  • HY-110042
    CCT018159

    		HSP Apoptosis CDK PERK Metabolic Disease Inflammation/Immunology Cancer
    CCT018159 is an ATP-competitive HSP90β inhibitor, with an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. CCT018159 induces cell cycle arrest and apoptosis in tumor cells, and inhibits invasion and angiogenesis. CCT018159 is applicable to cancer-related research .
    CCT018159
  • HY-13469
    Debio 0932
    5+ Cited Publications

    CUDC-305

    		 HSP Cancer
    Debio 0932 (CUDC-305) is an orally active HSP90 inhibitor, with IC50s of 100 and 103 nM for HSP90α and HSP90β, respectively .
    Debio 0932
  • HY-10214
    SNX-2112
    3 Publications Verification

    PF-04928473

    		 HSP Autophagy Cancer
    SNX-2112 (PF 04928473) is an orally active Hsp90 inhibitor, with a Kd of 16 nM for Hsp90 and IC50s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC50s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with Kds of 4 nM, 6 nM and 484 nM, respectively .
    SNX-2112
  • HY-B1434
    7-Aminocephalosporanic acid
    2 Publications Verification

    7-ACA

    		 Beta-lactamase Bacterial Antibiotic Infection
    7-aminocephalosporanic acid (7-ACA) is a HSP90β inhibitor and an antibiotic. 7-Aminocephalosporanic acid is the core chemical structure of the synthesis of cephalosporin antibiotics and an effective β-lactamase inhibitor .
    7-Aminocephalosporanic acid
  • HY-10942
    VER-82576
    5 Publications Verification

    NVP-BEP800

    		 HSP Cancer
    VER-82576 (NVP-BEP800) is a potent, orally available and selective Hsp90 inhibitor, with an IC50 of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC50s of 4.1 and 5.5 μM, respectively.
    VER-82576
  • HY-123035
    Gamendazole

    		HSP Akt EGFR Endocrinology
    Gamendazole, an indazole carboxylic acid (ICA), is an orally active, selective HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A) inhibitor. Gamendazole binds to the C-terminal nucleotide binding pocket of HSP90 and cause downregulation of clients AKT1 and ERBB2, but stabilizes the HSP90 heterocomplex. Gamendazole specifically inhibits the actin bundling function of EEF1A1, but does not bind to the nucleotide docking pocket nor inhibits the ribosome charging or protein translation functions of EEF1A1. Gamendazole, an antispermatogenic compound with antifertility effects, has the potential for reversible non-hormonal male contraceptive agent research .
    Gamendazole
  • HY-P11185
    Hsp90β decapeptide

    		HSP Cancer
    Hsp90β decapeptide is a C-terminal peptide of Hsp90β, which contains conserved TPR-domain MEEVD. Hsp90β decapeptide is able to bind tightly the Tah1 protein with a Kd of 1.0 μM .
    Hsp90β decapeptide
  • HY-117395
    PU-H54

    		HSP Cancer
    PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PU-H54
  • HY-175008
    Hsp90β-IN-1

    		HSP Others
    Hsp90β-IN-1 (Compound 7b) is a selective biotinylated inhibitor of heat shock protein 90β (HSP90β) with an IC50 = 0.33 μM .
    Hsp90β-IN-1
  • HY-178957
    Hsp90β-IN-2

    		HSP Cancer
    Hsp90β-IN-2 (Compound 16B) is a selective Hsp90β inhibitor with KDs of 225 nM and 73.32 μM against Hsp90β and Hsp90α. KUNB106 exhibits antiproliferative activity against MDA-MB-231 cells, A549 and SKOV-3 cells. KUNB106 can be used for the study of triple negative breast cancer .
    Hsp90β-IN-2
  • HY-178956
    KUNB106

    		HSP Cancer
    KUNB106 is a selective Hsp90β inhibitor with KDs of 91 nM and 38 μM against Hsp90β and Hsp90α. KUNB106 exhibits antiproliferative activity against MDA-MB-231 cells, A549 and SKOV-3 cells. KUNB106 can be used for the study of triple negative breast cancer .
    KUNB106
  • HY-168205
    HSP90-IN-33

    		HSP Apoptosis Cancer
    HSP90-IN-33 (compound 24e) is a potent Hsp90 inhibitor with Kd values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .
    HSP90-IN-33
  • HY-10215R
    Luminespib (Standard)

    VER-52296 (Standard); AUY922 (Standard); NVP-AUY922 (Standard)

    		 Reference Standards HSP Autophagy Apoptosis Cancer
    Luminespib (Standard) is the analytical standard of Luminespib. This product is intended for research and analytical applications. Luminespib (VER-52296) is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .
    Luminespib (Standard)
  • HY-B1434R
    7-Aminocephalosporanic acid (Standard)

    7-ACA (Standard)

    		 Beta-lactamase Reference Standards Bacterial Antibiotic Infection
    7-Aminocephalosporanic acid (Standard) is the analytical standard of 7-Aminocephalosporanic acid. This product is intended for research and analytical applications. 7-aminocephalosporanic acid (7-ACA) is a HSP90β inhibitor and an antibiotic. 7-Aminocephalosporanic acid is the core chemical structure of the synthesis of cephalosporin antibiotics and an effective β-lactamase inhibitor .
    7-Aminocephalosporanic acid (Standard)
  • HY-116053
    PU-11

    		HSP Neurological Disease
    PU-11 is a Hsp90α/Hsp90β inhibitor with IC50 values of 18.6 μM and 89.8 μM and Kd values of 2 and 4.2 μM. PU-11 binds to the ATP-binding pocket of Hsp90α and Hsp90β and displays selective binding preference for Hsp90α over Hsp90β, mediated by the nonconserved Hsp90α Ser52 residue. PU-11 can be used for the research of neurodegenerative disorders .
    PU-11
  • HY-162751
    Anticancer agent 249

    		HSP Apoptosis Cancer
    Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC50 of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC50 of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .
    Anticancer agent 249
  • HY-160430
    HSP90-IN-28

    		HSP Cancer
    HSP90-IN-28 (compound 12 h) is a potent and selective Hsp90 inhibitor with an IC50 of 0.46 μM for Hsp90α. HSP90-IN-28 exhibits ~48 fold selectivity versus other Hsp90β (IC50 = 22.28 μM) .
    HSP90-IN-28
  • HY-10214R
    SNX-2112 (Standard)

    PF-04928473 (Standard)

    		 Reference Standards HSP Autophagy Cancer
    SNX-2112 (Standard) is the analytical standard of SNX-2112 (HY-10214). This product is intended for research and analytical applications. SNX-2112 (PF 04928473) is an orally active Hsp90 inhibitor, with a Kd of 16 nM for Hsp90 and IC50s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC50s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with Kds of 4 nM, 6 nM and 484 nM, respectively .
    SNX-2112 (Standard)
  • HY-103063
    Iso-PU-H54

    		HSP Others
    Iso-PU-H54 is a purine-scaffold Grp94 inhibitor with an IC50 of 1.63 μM .
    Iso-PU-H54
  • HY-121723
    PU-H39

    		HSP Cancer
    PU-H39 (compound 9g) is a selective Grp94 inhibitor with an IC50 of 0.12 μM. PU-H39 exhibits 34% and 32% inhibition of MKNK2 and ROCK2 kinases respectively at 10 μM. PU-H39 can be used for the research of breast cancer .
    PU-H39

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: